- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed...
Recognized for discovery of cell-free fetal DNA in maternal blood and creation of noninvasive prenatal testing (NIPT), used by as...
VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company")...
World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to...
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing...
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review...
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7...
Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD),...
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis...
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway...
The report from The Insight Partners lists several stakeholders—including pharmaceutical and biotech companies, CROs, regulatory authorities, healthcare providers, and academic...
Agreement signed to establish collaboration between IAVI and IPDNew partnership aims to accelerate vaccine development and manufacturing for priority pathogens...
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical...
New AARP CEO Dr. Myechia Minter-Jordan to Discuss Innovations Shaping the Future of Aging and Well-Being WASHINGTON, Dec. 11, 2024...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6...
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing...
Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that...
The strategic partnership combines Dotmatics' deep expertise in scientific software with Databricks data intelligence expertise An upcoming webinar with Databricks...